S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

ACER Acer Therapeutics Inc

0.90

0.00 (0.00%)

31 Jul 2024 - Closed

Delayed by 15 minutes

Confidential Treatment Order (ct Order)

This regulatory filing also includes additional resources:
filename1.pdf

Acer Therapeutics (NASDAQ:ACER)
Historical Stock Chart
From Jul 2024 to Aug 2024

Click Here for more Acer Therapeutics Charts.

Acer Therapeutics (NASDAQ:ACER)
Historical Stock Chart
From Aug 2023 to Aug 2024

Click Here for more Acer Therapeutics Charts.

Acer Therapeutics Inc. News

Form 425 - Prospectuses and communications, business combinations
Thursday 9 November 2023 (9 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 9 November 2023 (9 months ago) • Edgar (US Regulatory)

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Thursday 2 November 2023 (9 months ago) • Edgar (US Regulatory)

Form 425 - Prospectuses and communications, business combinations
Thursday 2 November 2023 (9 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 2 November 2023 (9 months ago) • Edgar (US Regulatory)

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Acer Therapeutics Shareholders Vote "FOR" the Proposed Merger and Related Proposals
Thursday 2 November 2023 (9 months ago) • GlobeNewswire Inc.

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Monday 30 October 2023 (9 months ago) • Edgar (US Regulatory)

Form DEFM14A - Definitive proxy statement relating to merger or acquisition
Wednesday 11 October 2023 (10 months ago) • Edgar (US Regulatory)

Form 425 - Prospectuses and communications, business combinations
Thursday 31 August 2023 (11 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 31 August 2023 (11 months ago) • Edgar (US Regulatory)

Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
Thursday 31 August 2023 (11 months ago) • GlobeNewswire Inc.

Acer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA™ from Relief Therapeutics, Excluding the Geographical Europe
Thursday 31 August 2023 (11 months ago) • GlobeNewswire Inc.

More Acer Therapeutics Inc. News Articles

JP Morgan Chase

Verizon Communications

National Australia Bank

AUD vs US Dollar

Westpac Banking

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions